Transforming Alkermes into a Global Biopharmaceutical Company Case Solution & Answer

This Case is about FINANCIAL MANAGEMENT, MERGERS & ACQUISITIONS

PUBLICATION DATE: May 28, 2015 PRODUCT #: 215079-PDF-ENG

In the summertime of 2011, Jim Frates, CFO of Alkermes faced options about the best way to fund the acquisition of Dublin, Ireland-based Elan Drug Technologies (EDT) – a deal which was anticipated to close in the autumn.

The case describes the history of Alkermes, supplies details the financing alternatives, and advice about the planned amalgamation. The case gives pupils the possibility to pick a financing alternative, to assess the attractiveness of the amalgamation, and to examine the function CFOs play in biopharmaceutical companies.

Related Case Solutions:

Road Building or Road Pricing The Double Bottom Line: Profit and Social Benefit The Increasing Internationalization of the International Business Classroom: Cultural and Generational Considerations Integrative Programs in International Business: The Development of Undergraduate Cohort Programs Van Oord (A): Where Land And Water Meet Sugar & Spice Desserts: Strategic Position Defensibility An Overview of Cameroon KL Worldwide Enterprises Inc.: Putting Information Technology to Work Brand Israel: Marketing in Crisis Killing Craigslist: Entrepreneurship in the Online Apartment Rental Market